	A.Un- Audited Financial Results(Pro						/Re in I
	lo. Particulars	Unaudited Quarter ended			Unaudited Half year ended		(Rs. in La
Sr. No		3 months ended	3 months	ng 3 months ended in the previous	Year to date figures for Current	Year to date figures for the previous	Year End Previous
		30.09.13	ended 30.06.13	period 30.09.12	period ended	period ended	year end
$\frac{1}{2}$	Sales/Income from operation(Net of Excise duty)	2812.68			30.09.13	30.09.12	31.03.1
3	Toriei Obeignillo lucome	8.61	1835.4 8.9		4648.15	100.00	1252
4	Total Net Income from Operation Expenditure	2821.29	1844.4		17.54		104
<u> </u>	(a) Increase / decrease in starting		10.11.1	2030.55	4665.69	4464.23	12630
	(a) Increase / decrease in stock in trade & work in progress			+ -			
	(b) Consumption of raw materials	(116.08)	(384,99	380.44	(501.07)	40	
	(c) Employees Cost	1788.18	1786.55		3574.73	1047,94	2008
	(d) Depreciation	266.80	244.27	216.17	511.07	2410.95	8104
	(e) Other expenditure	98.79	98.49		197.28	434.48	946
	(f) Total	630.38	461.76	470.65	1092.14	195.57 923.45	393
	Profit(+)/Loss(-) from operations before Other	2668.07	2206.08	2219.93	4874.15	5012.39	1911
5	Income, Finance cost and Exceptional Items (2.4)	450.00				3012.38	13360
<u> </u>	Outer income	153,22	(361.68)		(208.46)	(548.16)	(720
_ [Profit (+) / Loss (-) from ordinary activities before Finance	0.00	1.98	0.99	1.98	1.98	(730. 52
	Cost & Exceptional tiems(5+6)	152.00					52
8	Finance Cost	153.22	(359.70)	(180.39)	(206.48)	(546.18)	/077
. 1	Profit(+)/Loss(-) from ordinary activities after Finance cost	250.13	226.86	243.48	476.99	480,37	(677, 1002
		(96.91)	(500.50)	l T			1002.
10	Exceptional Items	0.00	(586.56)	(423.87)	<u>(683,47)</u>	(1026.55)	(1679.9
2	Profit(+)/Loss(-) before Tax (9-10)	(96.91)	0.00	0.00	0.00	0.00	0.
	Tax Expenses(incl Deferred Tax)	0.00	(586.56)	(423.87)	(683.47)	(1026.55)	(1679.8
4	Net Profit(+)/Loss(-) after Tax (11-12) extraordinary Items	(96.91)	0.00 (586.56)	0.00	0.00	0.00	(499.9
5 1	Net Profit(+)/Loss(-) for the period(13-14)	0.00	0.00	(423.87) 0.00	(683.47)	(1026.55)	(1179.9
6	Paid up Fourity Share Copital (for	(96.91)	(586.56)	(423.87)	0.00	0.00	0.0
TF	Paid up Equity Share Capital (face value Rs.10/-each) Reserves excluding Revaluation Reserves as per	1317.82	1317.82	1317.82	(683.47)	(1026.55)	(1179.9
2 6	alance sheet of previous accounting year.			1017.02	1317.82	1317.82	1317.8
3 E	arning per share (EPS)	0.00	0.00	0.00	0.00		
- 10	Basic and diluted EPS before extraordings, its				0.00	0.00	1308.4
_ 0	not to be annualized)	/0.70					
- [9	b) Basic and diluted EPS after extraordinary items for	(0.74)	(4.45)	(3.22)	(5.19)	(7.79)	(8.96
Į.u.	o period, for the year to date and for the provious		1				(0.80
		(0.74)	(4.45)	(0.00)		i	
- "	on Promoters Shareholding Number of shares		(4.40)	(3.22)	(5.19)	(7.79)	(8.96
1.	Percentage of shareholding	7548453	7548453	7548453			
- P	omoters and Promoter group Shareholding	57.28	57.28	7548453 57.28	7548453	7548453	7548453
a)	Pledged/ Encumbered			37.20	57.28	57.28	57.28
_ I	Number of Shares						
_ (Pe	ercentage of Shares /as a % of the total	5448708	5448708	1441095	5448708	1444000	
I\$n	areholding of promoter & promoter group				<u> </u>	1441095	5448708
_][5	ricentage of Shares (as a % of the total	96.78	96.78	25.60	96.78	25.60	
	are capital of the company)	4, 3-				40.00	96.78
_ [b)	Non-encumbered	41.35	41.35	10.94	41.35	10.94	40.05
	mber of Shares	181087	40465=				41.35
- Pe	rcentage of Shares (as a % of the total	10100/	181087	4188700	181087	4188700	181087
	- very set of promoter & retornor of pribliphine	3.22					10100/
IPA	rcentage of Shares (as a % of the total	3.22	3.22	74.40	3.22	77.40	
100	are capital of the company)				<u> </u>	74.40	3.22

Notes:

- 1 The above results have been reviewed by the Audit Committee and thereafter, were taken on record by the Board of Directors of the Company at
 2 During the Quarter & Half Year and add. Only the Board of Directors of the Company at
- During the Quarter & Half Year ended 30th September 2013, 0 Investor complaints were received all of which have been attended by the company. No

 As the Company's historican series in the company in th
- As the Company's business activity falls within a single primary business segment viz Manufacturing of Bulk Drugs "the disclosure requirements of Drugs "the disclosure requirements of Drugs" and Drugs "the Drugs" and Drugs" and Drugs" and Drugs "the Drugs" and Drugs" and Drugs" and Drugs" and Drugs "the Drugs" and Drugs" and Drugs" and Drugs" and Drugs "the Drugs" and Drugs" and Drugs" and Drugs" and Drugs "the Drugs" and Drugs" an
- 4 Previous year figure are regrouped wherever necessary.

FOR MILWANI ASSOCIATES

Chartered Accountants

Place: Mumbal Date: 14.11.2013

On behalf of Board of Directors For Mangalam Drugs & Organics Ltd

V Chairman (Shri Govardhan M.Dhoot)

MANGALAM DRUGS & ORGANICS LTD.



STATEMENT OF ASSETS & LIABILITIES (Un-Audited)AS REQUIRED UNDER CLAUSE 41 OF LISTING AGREEMENT

	Particulars	Half Year ended(Un- audited)	(Rs.In Lacs Year Ended (Audited)
_		30.09,2013	31.03.2013
A	EQUITY AND LIABILITIES		51105.2015
٠ ا	Shareholders' funds	i	•
	(a) Share capital	1,317.82	1,317.82
-+	(b) Reserves and surplus	624.95	1,308.42
_	Sub Total -Shareholders Funds	1,942,77	2,626.24
2	Non-current liabilities		2,020.24
	(a) Long-term borrowings	4,478.01	4,423.53
-	(b) Deferred Tax Liabilities (Net)	145.27	4,423.33 145.27
_	Sub Total -Non-Current Liabilities	4,623,28	4,568,80
3	Current liabilities		4,508.80
1	(a) Short-term borrowings	3,501.60	2,866,27
ł	(b) Trade payables	885.24	1,069.42
+	(c) Other current liabilities	381.70	346.52
-+	Sub Total -Current Liabilities	4,768.54	4,282.21
_ -	TOTAL	11,334.59	11,477,25
В	ASSETS		11,477.23
1	I) Non-current assets	İ	i
ı	(a) Fixed Assets	5338.84	5513.36
-	(b) Long-term loans and advances	220.33	221.04
2	Sub Total -Non-Current Assets	5,559.17	5,734.40
4]	Current assets		3,734,40
ı	(a) Current Investments	18.44	18.44
- 1	(b) Inventories	2,678.28	3,105.96
- 1	(c) Trade receivables	2,811.12	2,386.57
	(d) Cash and cash equivalents	99.78	8.79
┰	(e) Short-term loans and advances	167.80	223.09
	Sub Total -Current Assets TOTAL	5,775.42	5,742.85
	IUIAL	11,334.59	11,477,25

Notes:1)Previous periods/years figures have been regrouped/rearranged wherever necessary.

On behalf of Board of Directors For Mangalam Drugs & Organics Ltd

Place:Mumbai Date: 14.11.2013

Chairman

(Shri Govardhan M.Dhoot)

For MILWANI ASSOCIATES

Charte ed Accountants

ER.N.:105405W 31/33, Dr. M. B.

Velkar St., Mumbai-400 002 BHARA'T

Rakes K. Miwani) Proprietor IY Dembership No.: 36099 F.R.N.:106405W

18, Bagaria House, 1st Floor, 31/33, Dr. M.B. Velkar Lane, Mumbai - 400 002. Tel.: 22036132 / 9821162679 E-mail: rakesh_milwani@hotmail.com

To The Secretary Stock Exchange, Mumbai Phiroze Jeejeebhoy Towers, Dalal Street. Mumbai – 400 001.

National Stock Exchange of India Limited "Exchange Plaza", Bandra - Kurla Complex, Bandra (E), Mumbai - 400 051.

LIMITED REVIEW REPORT

We have reviewed the accompanying statement of unaudited financial results of Mangalam Drugs & Organics Ltd. having its registered office at 292, Princess Street, Second Floor, Near Flyover, Mumbai - 400 002; for the quarter & half year ended 30th September, 2013 except for the disclosures regarding 'Public share holding' and 'Promoter and Promoter group share holding which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express such an opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the managers in which it is to be disclosed, or that it contains an terminal visit in the state of the contains and the managers.

F.R.N.:106405W

Place : Mumbai

Date: 14th November, 2013.

Membership No.36099 Firm Registration No.106405W